Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18 2023 - 7:05AM
Business Wire
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced that the Company will present at the Stifel 2023
Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30
p.m. ET.
A live webcast of the presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived replay of the presentation will be made available on the
same website for approximately 90 days following the
presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage
biopharmaceutical company committed to the development and
commercialization of new medicines to improve the lives of patients
diagnosed with cancer. Our pipeline is focused on novel small
molecule drugs that inhibit critical signaling pathways in cancer
that promote cancer cell survival and tumor growth, including
RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For
more information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230418005208/en/
Investors: Dan Calkins Investor Relations +1 781-469-1694
dcalkins@verastem.com
Nate LiaBraaten +1 212-600-1902 nate@argotpartners.com
Media: Lisa Buffington Corporate Communications +1 (781)
292-4205 lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jul 2023 to Jul 2024